The company is a medical devices company that has developed a novel therapeutic technology for the treatment of prostate cancer. The company’s apparatus uses non-invasive MRI imaging to identify prostate cell masses, and a trans-urethral ultrasound applicator that delivers precise thermal energy to tumor sites, stifling their progression. Treatment times are approximately 30 minutes, which is 6x faster than comparable technologies, and can be done multiple times per session due to the minimally invasive nature of the treatment. The company initiated its first in-human proof-of-concept study in September 2009.
The Cancer Consortium
Cancer News & Information Center
